Kodak says ‘substantial doubt’ it can stay in business
More than 130 Eastman Kodak Co says that there is an “important doubt” about his ability to stay at work and that he can force to meet his upcoming debt obligations.
The shareholders of the photo company records more than 13 percent of early transactions in the United States on Tuesday.
“Kodak has the debt to be paid within 12 months and if they become in accordance with the current conditions, it does not commit financing or current liquidity to fulfill these debt obligations.”
“These conditions arous an important doubt about Kodak’s ability to continue as an ongoing concern.”
New York -based Rochester said that as of June 30, $ 155 million (A239 million) cash and cash equivalent and $ 70 million in the US.
According to Wall Street Journal, Kodak said it would end the retirement income plan to pay the debt last year.
Kodak Chief Finance Manager David Bullwinkle said on Monday, how the company will meet the obligations to pay to all pension plan participants on Friday and to complete the return until December, he said.
Eastman Kodak Co, founded by George Eastman in 1880, is known for the popularization of photography at the beginning of the 20th century and was known for cake and instamatic cameras and yellow and red film boxes all over the world.
He could not keep up with the transition to Japanese competition and then to digital technology.
Kodak, increasing competition, digital photography continued to grow and increased debt after the struggle against the bankruptcy protection in 2012 applied.
The company was wounded by selling most of its business and patents while closing the camera production unit for the first time.
A year later, he received approval for the plan of the court’s supervision.
At that time, Kodak wanted to create himself again as a new, much smaller company focused on commercial and packaging pressure.
Kodak is approaching completion of a production facility to create arranged pharmaceutical products.
The company already makes irregular key starting materials for pharmaceuticals.
Production is expected to start in the appropriate facility later this year.
